Halozyme Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 55 U.S.-traded ETFs. HALO has around 12.9M shares in the U.S. ETF market. The largest ETF holder of HALO is the iShares Russell 2000 ETF (IWM), with approximately 2.94M shares. Investors may also find of interest that the ETF with the largest allocation to HALO stock is Invesco Dynamic Biotechnology & Genome ETF (PBE), with a portfolio weight of 3.05%. On average, U.S. ETFs allocate 0.32% of HALO to their portfolios.
Additionally, HALO is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with HALO as a holding is the ProShares Ultra NASDAQ Biotechnology (BIB), with a return of 45.12%.